39 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-ß hydrolysis.
University of Lille
Thiol-based angiotensin-converting enzyme 2 inhibitors: P1 modifications for the exploration of the S1 subsite.
Glaxosmithkline
Angiotensin converting enzyme inhibitors. 10. Aryl sulfonamide substituted N-[1-carboxy-3-phenylpropyl]-L-alanyl-L-proline derivatives as novel antihypertensives.
Rorer Central Research
Synthesis and biological evaluation of phosphonamidate peptide inhibitors of enkephalinase and angiotensin-converting enzyme.
TBA
Novel synthesis of (S)-1-[5-(benzoylamino)-1,4-dioxo-6-phenylhexyl]-L-proline and analogues: potent angiotensin converting enzyme inhibitors.
TBA
Synthesis and angiotensin-converting enzyme inhibitory activity of 3-(Mercaptomethyl)-2-oxo-1-pyrrolidineacetic acids and 3-(Mercaptomethyl)-2-oxo-1-piperidineacetic acids.
TBA
Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme by N-phosphonomethyl and N-carboxyalkyl dipeptides
TBA
4-Substituted proline derivatives that inhibit angiotensin converting enzyme and neutral endopeptidase 24.11.
TBA
Phage-encoded combinatorial chemical libraries based on bicyclic peptides.
Laboratory of Molecular Biology, Medical Research Council
Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by tricyclic benzazepinone thiols
TBA
α-Mercaptoacyl dipeptides that inhibit angiotensin converting enzyme and neutral endopeptidase 24.11
TBA
Discovery of Novel Nonpeptidic Proteasome Inhibitors Using Covalent Virtual Screening and Biological Evaluation.
The Chinese University of Hong Kong
A perspective on the development of small molecular neprilysin inhibitors (NEPi) with emphasis on cardiorenal disease.
Birla Institute of Technology and Sciences Pilani
Synthesis of cannabidiol-based compounds as ACE2 inhibitors with potential application in the treatment of COVID-19.
Universidade Federal de Minas Gerais
Thiol-based angiotensin-converting enzyme 2 inhibitors: P1' modifications for the exploration of the S1' subsite.
Glaxosmithkline
Highly potent dual-targeting angiotensin-converting enzyme 2 (ACE2) and Neuropilin-1 (NRP1) peptides: A promising broad-spectrum therapeutic strategy against SARS-CoV-2 infection.
China Pharmaceutical University
Bench-to-bedside: Innovation of small molecule anti-SARS-CoV-2 drugs in China.
Qufu Normal University
The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.
American University of Ras Al Khaimah
Enzyme inhibition as a potential therapeutic strategy to treat COVID-19 infection.
Kingston University
Discovery of honokiol thioethers containing 1,3,4-oxadiazole moieties as potential α-glucosidase and SARS-CoV-2 entry inhibitors.
Zhengzhou University
Synthetic Peptides That Antagonize the Angiotensin-Converting Enzyme-2 (ACE-2) Interaction with SARS-CoV-2 Receptor Binding Spike Protein.
University of Groningen
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
University of California San Francisco (Ucsf)
Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-β-lactamases.
Qpex Biopharma
The Other Angiotensin II Receptor: AT
Centre Hospitalier Universitaire Vaudois (Chuv) and University of Lausanne (Unil
The first mechanism-based inactivators for angiotensin-converting enzyme.
Baxter Diagnostics
Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Array Biopharma
Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design.
Vernalis (R&D)